On July 31, XTALPI rose 5.12% in regular trading, trading at HK$6.77/share, with turnover of HK$154 million. The stock rebounded after several consecutive days of weakness triggered by a profit warning.

On the news front, JPMorgan recently initiated coverage on XTALPI with an Overweight rating and a target price of HK$10, implying approximately 48% upside from current levels. The bank expressed a positive outlook on the company's diversified business centered on AI-driven drug discovery services and robotic wet laboratories, noting that China's AI pharmaceutical R&D industry is transitioning from commercial exploration toward early commercialization, which may trigger a valuation re-rating.

Within the Life Sciences Tools & Services sector, INSILICO rose 7.09%, GENSCRIPT BIO rose 3.66%, JOINN rose 3.52%, WUXI BIO rose 2.80%, and WUXI APPTEC rose 2.35%, reflecting broad sector recovery that further supported the stock's rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)